Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.

Diabetes, obesity & metabolism

Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.

Journal of cardiovascular pharmacology

Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.

Drug design, development and therapy

Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.

Obesity pillars

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

HIV medicine

Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study.

Pharmaceutics

Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.

Nutrients

Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.

Nutrients

🚨 $HIMS CHIEF MEDICAL OFFICER, ANANT VINJAMOORI, AT THE FDA PEPTIDES MEETING: "My company [Hims & Hers] intends to offer peptide therapy if allowed. We intend to do so with guardrails because we think that is in the best interest of patients." "We would, in fact, benefit https://t.co/bR3aUJC27D https://t.co/KyMuYsXyDL

🚨 The next bull 🐂 market will be longevity with peptides and $HIMS & $ENHA are at the very forefront of this new market. • The global peptide therapeutics market size is projected to grow from USD 164.0 billion in 2026 to USD 294.6 billion by 2033, at a CAGR of 8.7% from 2026 https://t.co/1JdUEXGX9Q

Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC-157 to the 503A Bulks List for use in compounding for ulcerative colitis. While this is only a recommendation and not a final https://t.co/aqHs90MxkF

🚨 BPC-157 and KPV just received favorable PCAC votes for the 503A Bulk Drug Substances List - 2 of 7 peptides now recommended ✅ Today on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) delivered important non-binding recommendations during day one of https://t.co/iNlQaFx9lH

$ENHA's intended protocols if the FDA decides to include peptides on the 503A Bulks List: - Wolverine Stack (BPC-157 + TB-500): pairs localized tissue repair with systemic soft-tissue recovery, with particular relevance for athletic recovery - GLOW Stack (BPC-157 + TB-500 + https://t.co/b9xPkfkCos

$HIMS FDA PEPTIDE PANEL VOTES YES ON BPC-157 8 YES 6 NO 1 ABSTAIN This is the first major development from the FDA’s Pharmacy Compounding Advisory Committee meeting. To be clear, this does not mean BPC-157 is FDA approved. The committee is only advising whether BPC-157

An FDA advisory panel spent two days this week deciding the fate of seven peptides. Here's what happened, and why the "peptides good or bad" framing going around misses the actual question. The FDA's Pharmacy Compounding Advisory Committee met July 23 and 24 to review BPC-157, https://t.co/bbxNbhClv0

Some acronyms you’ll see a lot in peptide discussions and what they mean: API: Active Pharmaceutical Ingredient = Basically the actual active peptide as opposed to fillers, stabilizers, or BAC water. Often used loosely to mean "the raw powder," though the powder isn't always